Top Markets
#1 Akedo Akedo +71.59%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +48.61%
#4 Cross Cross +43.52%
#5 Black Phoenix Black Phoenix +33.78%
#6 Cap Cap +25.61%
#7 Velvet Velvet +25.32%
#8 Ravencoin Ravencoin +17.91%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.35%
#10 DoubleZero DoubleZero +12.07%
Coin of the day
Akedo Akedo
설정
언어
한국어
통화
USD
테마
NeuBase Therapeutics, Inc. NeuBase Therapeutics, Inc.

NeuBase Therapeutics, Inc.

NBSE
주식 순위 #39174
Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics,... Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics, Inc. is dedicated to pioneering therapeutic solutions for rare genetic disorders and various cancers stemming from aberrant genes. At the core of its approach is the proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform. This technology is being utilized to target ailments such as Huntington's disease (HD) and myotonic dystrophy, in addition to a broader spectrum of genetic conditions and applications within oncology. The company's leading therapeutic candidates encompass NT0100, a PATrOL-powered anti-gene therapy for Huntington's disease; NT0200, another PATrOL-enabled anti-gene solution for myotonic dystrophy type 1; and NT0300, a PATrOL-based treatment specifically engineered to address the mutated KRAS gene. NeuBase Therapeutics, Inc. maintains its headquarters in Pittsburgh, Pennsylvania.
주가
$0.378
마지막 동기화: 2024-05-24
시가총액
$618.41K
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 NeuBase Therapeutics, Inc. (NBSE)

카테고리

Healthcare
NeuBase Therapeutics, Inc. (NBSE)의 매출
Aug 2026 기준 매출 TTM: 0
NeuBase Therapeutics, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 0 대비 동일입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
NeuBase Therapeutics, Inc.의 수익 기록 (2026 ~ 2026)
매년 말 매출
연도 매출 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 매출
회사 매출 매출 차이 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE